Standex International Corp. (SXI) Financials Nov 14, 2014,
Standex International Corp. (SXI) Financials Nov 14, 2014, 4:28 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Standex International Corp.
Fiscal year is July-June. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 578.45M 581.37M 634.64M 701.26M 716.18M
Cost of Goods Sold (COGS) incl. D&A 395.05M 389.83M 426.16M 475.16M 477.91M
COGS excluding D&A 380.64M 376.56M 412.67M 459.62M 463.32M
Depreciation & Amortization Expense 14.41M 13.27M 13.49M 15.55M 14.59M
Depreciation 11.1M 10.9M 10.8M 12.9M 12.2M
Amortization of Intangibles 3.31M 2.37M 2.69M 2.65M 2.39M
Gross Income 183.4M 191.54M 208.48M 226.1M 238.27M
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 138.77M 137.81M 147M 156.7M 165.79M
Research & Development 3.6M 4M 4.4M 4.4M 4.8M
Other SG&A 135.17M 133.81M 142.6M 152.3M 160.99M
Other Operating Expense 0 0 0 0 0
Unusual Expense 3.77M 1.84M 1.69M 1.5M 3.22M
EBIT after Unusual Expense (3.77M) (1.84M) (1.69M) (1.5M) (3.22M)
Non Operating Income/Expense 2.16M 3.17M 5.3M (4.19M) 1.82M
Non-Operating Interest Income - 0 0 0 0
Equity in Affiliates (Pretax) 0 - - - -
Interest Expense 3.62M 2.11M 2.28M 2.47M 3.28M
Gross Interest Expense 3.62M 2.11M 2.28M 2.47M 3.28M
Interest Capitalized 0 0 0 0 0
Pretax Income 39.4M 52.95M 62.82M 61.23M 67.8M
Income Tax 11.44M 14.92M 15.91M 15.91M 18.05M
Income Tax - Current Domestic 3.51M 10.81M 5.76M 11.13M 10.07M
Income Tax - Current Foreign 2.6M 4.79M 7.77M 7.18M 11.33M
Income Tax - Deferred Domestic 6.08M (2.08M) 2.78M (422,000) (2.39M)
Income Tax - Deferred Foreign (758,000) 1.41M (407,000) (1.98M) (950,000)
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 27.96M 38.03M 46.91M 45.32M 49.75M
Minority Interest Expense 0 0 0 0 0
Net Income 27.96M 38.03M 46.91M 45.32M 49.75M
Extraordinaries & Discontinued Operations 739,000 (2.66M) (16M) (474,000) (6.88M)
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 739,000 (2.66M) (16M) (474,000) (6.88M)
Net Income After Extraordinaries 28.7M 35.37M 30.91M 44.85M 42.87M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 27.96M 38.03M 46.91M 45.32M 49.75M
EPS (Basic) 2.31 2.83 2.47 3.57 3.39
Basic Shares Outstanding 12.44M 12.48M 12.52M 12.56M 12.61M
EPS (Diluted) 2.26 2.77 2.42 3.51 3.35
Diluted Shares Outstanding 12.69M 12.75M 12.79M 12.78M 12.78M
EBITDA 59.04M 67.01M 74.98M 84.94M 87.07M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Dollars and Sense: Affordable Cars in Raleigh Listen up, folks. These days, unless you're on the hunt for a fancy ride decked out with every bell and whistle, the idea of nabbing a car under ten grand almost sounds like a fairytale. But Auction Direct USA in Raleigh is making this dream a reality. That’s right, a whole fleet of used cars, all priced under $10,000, is...
Continue Reading
Revenue Surge but Margin Squeeze Out there in the land of HVAC, Lennox International (NYSE: LII) just dropped its third quarter earnings for 2026. Sure, they raked in a solid $1.6 billion—up a hearty 10%. But all that glitters ain't gold, and the company's operating income took a hit down to $312 million, shedding a cool five percent from last year. Challenges Weighing...
Continue Reading
The True Stories Behind Exorcisms In the complex landscape of media today, EWTN Studio's latest docuseries, In Jesus' Name, steps into the ring with tales that outstrip Hollywood's beloved fright flicks. Forget about the jumpscares and the special effects next to those greased-up eggs you're munching on. This series drills right to the bone of reality—a candid look at...
Continue Reading
Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...
Continue Reading
Record Financing Applications, But Not All is Rosy Diving headlong into this 1West data is like clutching at a double-edged sword. On one side, we've got record-breaking numbers—48,975 financing applications in Q3 alone. That’s a staggering 25% hike over last year. But before you pop the champagne, let's pivot to the other edge: dwindling financial health. With the...
Continue Reading
Stepping up to Spotlight Courage In a world that often seems to teeter on chaos, it's those unsung heroes—the first responders—who stand ready to turn panic into repose. October 28th saw Times Square in New York City transform into a beacon of appreciation as the First Responders Children's Foundation (FRCF) applauded nineteen fearless foes of danger. Picture that...
Continue Reading
Electricity Powerhouse Unleashes Ambitious Plan If you thought American Electric Power (NASDAQ:AEP) was just cruising along, think again. This week, they rolled out an eye-popping $100 billion plan to supercharge their infrastructure and meet soaring electricity demands. It’s like they’re building the future of power right in front of our eyes. Third-quarter earnings...
Continue Reading
Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...
Continue Reading
Cloopen Steps Away from Public Market Scene Here's a tale simmering on the corporate backburner: Cloopen Group Holding Limited, that cloud juggernaut over in China, has gone all private on us. The ink is drying on their merger with SummerX Holdings Limited, under the overarching umbrella of SpringX Holdings. So, now this communications outfit has slipped out of the public...
Continue Reading
Ever stood in a place where history feels so heavy you can almost touch it? That's Lazikou, a gorge in southern Gansu, where ninety years ago, young soldiers of China's Red Army faced a seemingly impassable barrier. Yet, they managed to climb, transform a military retreat into legend, and essentially shape the nation's path ahead. It's a feat that still sends ripples...
Continue Reading
Top 5 Most Recently Viewed Articles
Aeroderivative Gas Turbine Market Overview The Aeroderivative Gas Turbine market is experiencing remarkable growth, driven by increasing demands for efficient power generation and technological innovations. According to recent analysis, the market is projected to surge to an estimated value of USD 6.79 billion by 2034, marking a compound annual growth rate (CAGR) of...
Continue Reading
Chain.io Unveils New Snowflake Connectivity Chain.io has introduced an exciting connected application aimed at boosting the capabilities of supply chain teams. This innovative tool provides seamless access to supply chain data, paving the way for deeper insights and improved operational efficiency. Navigating the Complexities of Supply Chain Data Logistics and supply...
Continue Reading
Antalpha's Impressive Third Quarter Performance Antalpha Platform Holding Company (NASDAQ: ANTA) has recently unveiled promising financial results for the third quarter of this year. This period has proven pivotal as the company marked an extraordinary 62% growth in revenue over the previous year, highlighting the effectiveness of their Prime lending platform. Rapid...
Continue Reading
Understanding Class Actions and Your Rights If you've faced losses in your investments with Block, Inc. (XYZ), you may feel overwhelmed and uncertain about your next steps. Class action lawsuits can be an effective way for shareholders like you to seek justice and accountability from companies. The Gross Law Firm is reaching out to encourage affected investors to take...
Continue Reading
Acumen Pharmaceuticals Advances in Alzheimer’s Research Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a pioneering clinical-stage biopharmaceutical company, is at the forefront of developing a promising new treatment aimed at combating Alzheimer's disease. This innovative approach focuses on targeting soluble amyloid beta oligomers (A?Os), a significant physiological...
Continue Reading